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On the basis of a previously observed correlation between the antimicrobial activity and DNA binding
strength of dicationic molecules, a series of 10 dicationically substituted bis-benzimidazoles were tested for
activity in the rat model ofPneumocystis carinii pneumonia. One of the compounds, 1,4-bis[5-(2-imidazolinyl)-
2-benzimidazolyl]butane, was found to be more potent and less toxic than pentamidine.
The synthesis and antiprotozoal activity of pentamidine
[1,5-di(4-amidinophenoxy)pentane] were first reported in the
late 1930s (17). The compound has been used clinically
against African trypanosomiasis (1), antimony-resistant
leishmaniasis (7), and Pneumocystis carinii pneumonia
(PCP) (14, 15). Until recent studies suggested that the
combination of trimethoprim and sulfamethoxazole or dap-
sone was as effective as and considerably less costly than
pentamidine, aerosolized administration of pentamidine was
fast becoming the method of choice for primary prophylaxis
for PCP in AIDS patients (11, 13).
Studies in our laboratory aimed at developing more effec-
tive antimicrobial analogs of pentamidine led to the synthesis
of a large series of pentamidine-related compounds and the
testing of these compounds in a rat model of PCP (21, 22).
One of the compounds from this series, 1,3-di[4-(2-imidazoli-
nyl)-2-methoxyphenoxy]propane, was found to be approxi-
mately 10 times more potent than pentamidine and, unlike
the parent drug, demonstrated significant activity when
given by the oral route of administration (16, 20). In addition,
selected pentamidine analogs were found to be active against
Plasmodium falciparum (4), Cryptosporidium parvum (5),
Toxoplasma gondii (18), Giardia lamblia (2), and Leishma-
nia mexicana amazonensis (4). Furthermore, evidence that
strongly indicated that the antimicrobial activity of these
compounds correlated with their ability to bind with an AT
preference in the minor groove ofDNA was presented (2, 3,
8). In an attempt to exploit this relationship between DNA
binding and antimicrobial potency, a series of dicationically
substituted bis-benzimidazoles, previously synthesized and
shown to be potent DNA binding agents (10), were tested for
their activity against rat PCP.
The synthesis, physical properties, and DNA binding
characteristics of the 10 bis-benzimidazoles chosen for the
study have been detailed in previous communications (10,
19). Likewise, the pentamidine dihydrochloride was synthe-
sized in our laboratory according to standard procedures
(12).
The induction, treatment, and quantification of rat PCP
were carried out according to published methods (16, 22) in
the following manner.
Adult male Sprague-Dawley rats, barrier raised, not cer-
tified virus free, and weighing 150 to 200 g, were obtained
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from Hilltop Laboratories (Scottsdale, Pa.). The individually
caged animals were begun immediately upon arrival on an
immunosuppressive regimen consisting of a low-protein
(8%) diet (Zeigler Brothers, Gardner, Pa.) and drinking
water containing tetracycline (0.5 mg/ml) and dexametha-
sone (1.0 jig/ml). This regimen was continued for the next 8
weeks with fluid intake being monitored daily and animals
being weighed weekly. At the beginning of the sixth week,
animals were divided into groups of eight or more animals
per group and the test compounds were administered either
by daily intravenous injection at the appropriate dose for 14
days or orally by gavage daily for 14 days. Saline- and
pentamidine-treated groups were included as negative and
positive controls, respectively. Compounds tested in differ-
ent experiments were compared directly with one another
when there was no significant difference in the control
groups. In these cases, the controls were pooled and statis-
tical comparisons were made between individual groups and
pooled controls.
All animals were sacrificed at the end of the eighth week
by chloroform inhalation, and the right lung was inflated in
situ with 10% formalin and fixed for histologic examination.
The fixed lung tissue was sectioned longitudinally and
stained with Grocott's methenamine silver stain which se-
lectively stains the walls of the P. carinii cysts. Stained
sections were coded, and each section was scored by two
examiners using a blinded protocol. Sections were read and
scored according to published methods (23): 0.5, fewer than
10 cysts counted per two fully examined sections; 1, scat-
tered cysts with <10% of lung tissue involved; 2, scattered
cysts with limited intense focal involvement and 10 to 25% of
lung tissue involved; 3, scattered cysts with numerous
intense areas of focal involvement and 26 to 50% of lung
tissue involved; 4, cysts found throughout the tissue with
numerous very intense focal areas of involvement having
>50% of lung tissue involved.
The left lung was weighed, ground through a no. 60 wire
mesh screen, and suspended 1:10 (wt/vol) in 10 mM 1-mer-
captoethanol-Hanks' balanced salts solution without ca-
tions. Slides were prepared by spotting 5 ,il of lung homoge-
nate diluted 1:10 in Hanks' balanced salts solution with
3-mercaptoethanol and allowed to air dry. The slides were
stained with cresyl violet (6), and the cysts were counted by
a blinded protocol. The number of cysts per gram of original
lung tissue was calculated, and the groups were reported as
the percentages of saline-treated controls (20).
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TABLE 1. Activity of bis-benzimidazole compounds against PCP by daily intravenous injection
R N N R
Mean No. of animals with the
Compound X Ra Dose histologic following histologic score: Toxicity at No. of cysts/g of lung tissue(mg/kg) score (n) 05210 mg/kg" (% control ±- SE [nJ)
Saline 3.6 (80) 0 0 5 19 56 100.00 ± 8.11 (48)-
Pentamidine 10.0 1.2 (63) 13 35 12 3 0 ++ 3.66 + 0.64 (46)d
5.0 1.7(12) 1 3 7 1 0 0 NDe
1 CH2 Am 10.0 0.6 (8) 7 1 0 0 0 0 ND
2 CH2 Im 10.0 0.8 (8) 4 4 0 0 0 ++ 1.57 + .49 (8)d
3 (CH2)2 Am 10.0 0.7 (10) 7 3 0 0 0 ++ 0.99 ± 0.36 (lO)d
4 (CH2)2 Im 5.0 0.6 (12) 9 3 0 0 0 +++ 1.71 ± 0.39 (12)d
5 (CH2)3 Am 10.0 3.0 (12) 0 1 1 7 3 + 31.82 ± 5.19 (12)d
6 (CH2)3 Im 10.0 1.4 (12) 1 7 3 1 0 + 4.43 ± 1.37 (12)d
7 (CH2)4 Am 10.0 0.6 (12) 10 2 0 0 0 0 0.30 ± 0.11 (12)d
8 (CH2)4 Im 10.0 0.5 (12) 12 0 0 0 0 0 0.08 ± 0.02 (12)d
9 (CHI2) Am 5.0 2.1 (12) 1 0 8 3 0 +++ 15.55 ± 2.23 (12)d
10 -CH=CH- Am 5.0 1.5 (12) 1 5 5 1 0 +++ 2.68 ± 0.47 (12)d
NH N
aAmn= -Cf Jm= 4
oNNKz ND
I See text for explanation of toxicity scores.
c Saline controls = 3.7 x 107 cysts per g of lung tissue.
d p < 0.001 versus saline.
I ND, not done.
The animals were observed closely for a 10- to 15-min
period following injection of the test drug for signs of acute
toxicity, especially for hypotension (paling of the eyes,
lethargy, paling of the paws, and decreased body tempera-
ture). Their health and general well-being were observed and
recorded on a daily basis for the remainder of the experi-
ment. Excessive weight loss (a >25-g weight loss over
2-week dosing period was considered excessive in compar-
ison with saline controls) was considered a key indicator of
declining health due to drug toxicity. At necropsy, livers,
spleens, kidneys, and pancreases from all animals were
examined for histopathology.
While the toxicity information reported in this study
should not be considered definitive and is mainly anecdotal
in nature, these evaluations do allow for a comparison of the
relative toxicities of the compounds. Toxicity of the test
compounds was evaluated at 10 mg/kg of body weight or the
highest soluble concentration, according to the previously
described methods (22), by the following criteria.
"0" indicated no local, clinical, or histologic toxicity.
"+ " indicated that all animals survived the test dose without
observable distress. Minimal signs or no signs of hypoten-
sion were observed. Some excess weight loss and/or mild
signs of local toxicity at the injection site were noted. No
histopathology was noted. "++" indicated that all animals
survived the test dose with signs of hypotension or other
clinical side effects and/or definable histopathology.
"++ +" indicated that an acute toxic effect was seen after a
single dose with symptoms compatible with severe hypoten-
sion and/or a sharp decrease in the animals' health after
multiple doses. Death occurred in fewer than 50% of the
animals, resulting in a reduced screening dose. +++++"
indicated that death occurred in more than 50% of the
animals with a resulting reduction in screening dose.
The mean t test was used to calculate theP values of each
test group in comparison with pooled saline-treated and
pentamidine-treated groups. The statistical analysis was
carried out by using the StatsPlus software package (Human
Systems Dynamics, Northridge, Calif.) on an Apple IIe
computer.
Table 1 lists the compound structures, activities against
rat PCP, and toxicities of the 10 bis-benzimidazoles. The
activities and toxicity scores of the test compounds were
compared with those of the pentamidine- and saline-dosed
control groups. An examination of the data in Table 1 reveals
that all of the bis-benzimidazoles exhibited significant anti-
PCP activity when test groups were measured as the per-
centage of cysts found in the saline controls. One of the
compounds (compound 8) appeared to be clearly superior to
the rest of the derivatives when evaluated by either cyst
counts or histologic score. It was necessary to test three of
the compounds (compounds 4, 9, and 10) at 5 mg/kg/day
rather than at the standard screening dose of 10 mg/kg/day
because of toxicity. The histologic scores for these com-
pounds were compared with those for pentamidine given at
the 5-mg/kg/day dose level. At 10 mg/kg, compounds 4 and 9
induced symptoms consistent with acute hypotension while
the higher dose of compound 10 resulted in vascular damage
near the injection site and necrosis of the surrounding tissue.
One of the compounds (compound 8) was chosen for
additional testing on the basis of the excellent activity in the
original screen (mean histologic score = 0.5, and no. of cysts
per gram of lung tissue = 0.08% of control) and the absence
of toxicity at the screening dose. The results of the dose-
response studies with compound 8 are detailed in Table 2.
Compound 8, 1,4-bis[5-(2-imidazolinyl)-2-benzimidazolylI
butane, showed excellent activity down to a dose of 2.5
mg/kg/day and produced a significant reduction, compared
with the saline control group, in the number of cysts per
gram of lung tissue at a dose of 1 mg/kg/day. In addition, the
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TABLE 2. Dose-response activity of 1,4-bis[5-(2-imidazolinyl)-2-benzimidazolyl]butane (compound 8) against PCP
No. of animals with the following
Compound Dose Toxicitya Mean histologic histologic score: No. of cysts/g of lung tissue(mgtkg/day) score (n) (% of control t SE [n])
0.5 1 2 3 4
Saline 3.6 (24) 0 0 1 8 15 100.00 ± 7.61 (36)b
Pentamidine 10.0 ++ 1.1 (23) 2 18 3 0 0 2.68 + 0.41 (35)C
Compound 8 15.0d 0 0.5 (9) 9 0 0 0 0 0.12 ± 0.06 (9) e
10.0" 0 0.5 (12) 12 0 0 0 0 0.08 ± 0.02 (12)c.e
5.0" 0 0.7 (11) 7 4 0 0 0 1.40 ± 0.65 (11)C
2.5d 0 1.5 (12) 1 7 2 2 0 11.40 ± 7.84 (12)C
1.0d 0 NDf 43.34 ± 8.21 (12)c.e
25.0w 0 2.0 (11) 2 1 5 2 1 28.22 ± 12.39 (11)C.e
a See text for explanation of toxicity scores.
b Saline control = 4.2 x 107 cysts per g of lung tissue.
c P < 0.001 versus saline.
d Administered intravenously.
e P < 0.005 versus pentamidine.
f ND, not done.
g Administered orally.
compound showed no overt toxicity when administered at 15
mg/kg/day for 14 days. The compound was not tested at
higher dose levels in rats for activity against PCP or toxicity
because of insufficient quantities of material. However, an
abbreviated dosing period (5 days) at 20 mg/kg produced a
toxic effect similar to that seen with pentamidine. Finally,
compound 8 exhibited significant activity when given per os
at 25 mg/kg/day. No anti-P. carinii activity is detectable
when pentamidine is given by oral administration at doses of
up to 40 mg/kg/day (data not shown).
All of the compounds in this study were previously shown
to bind to DNA, with a strong preference for AT-rich regions
(10). The strongest DNA binding agents [both to calf thymus
DNA and to the nucleic acid homopolymers poly(dA).
poly(dT) and poly(dA-dT) poly(dA-dT)] were compounds
3, 4, 7, 8, and 10, and each one of these agents was highly
effective in the rat model of PCP. Compounds 1, 2, 5, 6, and
9 exhibited intermediate DNA binding strength relative to
the rest of the group. However, compounds 1 and 2 showed
excellent activity in the PCP model. Pentamidine demon-
strated intermediate DNA binding strength relative to the
bis-benzimidazoles. It is obviously not possible to make a
quantitative comparison between the specific in vitro activ-
ity of these molecules and their in vivo efficacy. However,
intermediate-to-strong DNA binding of bis-benzimidazoles
seems to be a prerequisite for obtaining good activity against
PCP. For example, a monocationic analog of compound 3
was found to be a very poor DNA binding agent (10) and was
devoid of anti-PCP activity at 10 mg/kg (data not shown).
In conclusion, a potential new agent for the treatment of
PCP has been discovered. Compound 8, 1,4-bis[5-(2-imida-
zolinyl)-2-benzimidazolyl]butane, was found to be more
effective and less toxic than pentamidine in the rat model.
This study is also noteworthy in that it represents the first
successful attempt to select and test new pentamidine-
related compounds for antimicrobial activity based on a
proposed mechanism of action. While any attempt to corre-
late a specific in vitro activity of a molecule with its in vivo
action is difficult, the data from this study appear to justify
the future design of pentamidine-like compounds as antimi-
crobial agents on the basis of their DNA binding strength. A
recent study in our laboratory demonstrated a strong corre-
lation between DNA binding strength and in vitro antigiar-
dial activity of pentamidine analogs (2). An excellent corre-
lation among the inhibition of topoisomerase, DNA binding
affinity, and antigiardial activity of this series of bis-benzi-
midazoles was also observed (3). We have also reported that
several of the more effective anti-P. carinii compounds are
potent inhibitors of type II topoisomerase relaxation activity
from P. carinii (9). The topoisomerase-inhibitory activity of
pentamidine-related compounds appears related to their
ability to bind to DNA. Future studies will be aimed at
designing and synthesizing more effective DNA binding
agents and inhibitors of topoisomerase II and testing these
compounds for their antimicrobial activity.
This work was supported by a contract (NOl-AI 72648) and a
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